We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
You must tell DVLA if you have muscular dystrophy - download the correct form to let them know.
Guillain-Barré syndrome is a rare neurological condition which can occur following Zika virus infection.
Find out about the long-term effects some people can have after having COVID-19.
Advice and guidance on the health needs of migrant patients for healthcare practitioners.
Projects granted during 2015 that have a primary purpose of basic research: musculoskeletal system.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 4 July 2025, approved nogapendekin alfa inbakicept (Anktiva) for adults with BCG-unresponsive non-muscle invasive bladder cancer, where the disease remains confined to the inner lining of the bladder and may...
Projects granted during 2015 that have a primary purpose of translational and applied research: musculoskeletal disorders.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).